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OBJECTIVE—In type 1 diabetes, allogeneic pancreatic islet
transplant restores insulin production, but life-threatening immu-
nosuppression is required to avoid graft rejection. Induction of
antigen (Ag)–speciﬁc tolerance by cell therapy with regulatory
T-cells (Tregs) represents an attractive alternative approach but
its therapeutic efﬁcacy in islet transplant remains to be deter-
mined. Among the different subsets of CD4
 Tregs, the T
inducible regulatory type 1 (Tr1) cells can be generated from
naive T-cells in the presence of interleukin-10 (IL-10) and repre-
sent one promising therapeutic choice. This study was designed
to deﬁne the efﬁcacy of Tr1-cell therapy in preclinical models of
islet transplant.
RESEARCH DESIGN AND METHODS—Non–Ag-speciﬁc
polyclonal Tr1 cells and donor Ag-speciﬁc Tr1 cells were trans-
ferred, in the absence of any pharmacological treatment, in two
distinct mouse models of islet transplant. The two models
differed in their therapeutic stringency, based on the mean
rejection time of untreated mice that underwent a transplant.
RESULTS—Transfer of polyclonal Tr1 cells engendered graft
tolerance only in the nonstringent mouse model. Conversely, cell
therapy with Ag-speciﬁc Tr1 cells induced an IL-10–dependent
tolerance in the stringent mouse model of islet transplant. The
therapeutic advantage of Ag-speciﬁc Tr1 cells over polyclonal
Tr1 cells was due to their donor Ag speciﬁcity.
CONCLUSIONS—These results demonstrate that Tr1-cell ther-
apy leads to tolerance in settings of islet transplant and that its
therapeutic efﬁcacy is highly dependent on the antigen speciﬁcity
of these cells. Diabetes 59:433–439, 2010
P
ancreatic islet transplant remains the only thera-
peutic option currently available for individuals
with established type 1 diabetes and, when used,
it is largely restricted to individuals in whom
conventional insulin therapy fails to maintain adequate
metabolic control. In 2000, Shapiro et al. from Edmonton
demonstrated that a steroid-free immunosuppressive
treatment results in successful transplant of pancreatic
islets (1). A larger multicenter trial conﬁrmed these initial
ﬁndings, but also unfortunately revealed that insulin inde-
pendence was not sustainable and graft function was lost
in nearly all patients 5 years after transplant (2). Many
pharmacological-based attempts to prevent rejection of
transplanted islets have been tried, with some recent
reports suggesting signiﬁcant progress toward that goal
(reviewed in 3). However, each of these approaches is
based on continuous administration of immunosuppres-
sants with well-described and deleterious side effects. One
attractive alternative would involve the induction of graft-
speciﬁc tolerance, allowing for immunosuppression to be
withdrawn without the risk of graft rejection.
To this end, interest has continued to grow for the use of
T regulatory cells (Tregs) as a therapeutic means to
modulate undesired immune responses and to achieve
antigen (Ag)–speciﬁc tolerance (4). Tregs are a speciﬁc
subset of T-cells that keep the immune system under
control and thereby preserve homeostasis and tolerance
to self-antigens (5). The CD4
 Tregs have been catego-
rized into two major subgroups based on their ontogeny.
These include the naturally occurring forkhead box P3
(FoxP3)
CD4
CD25
 Tregs (nTregs), which develop in
the thymus and are present in normal naive mice and
healthy individuals from birth, as well as the inducible
Tregs, which are generated in the periphery under various
tolerogenic conditions (reviewed in 6). Many different
subsets of inducible Tregs have been described. Among
these, the T regulatory type 1 (Tr1) cells, which constitu-
tively produce high levels of interleukin-10 (IL-10) in the
absence of IL-4 (IL-10
IL-4
), are among the most exten-
sively characterized subsets (reviewed in 7).
In terms of relationship between Tregs and therapeutic
effectiveness, it has been reported that one exceptional
type 1 diabetic patient who remained insulin-free 11 years
after islet transplant had a signiﬁcantly higher frequency of
circulating nTregs, compared with healthy age-matched
control subjects (8). Similarly, IL-10 production by periph-
eral blood mononuclear cells isolated from insulin-inde-
pendent patients who underwent islet transplant was
signiﬁcantly higher compared with that produced by insu-
lin-dependent subjects who underwent a transplant (9).
These ﬁndings suggest an active role of Tregs in maintain-
ing long-term tolerance after allogeneic islet transplant in
autoimmune type 1 diabetic patients and support efforts to
develop a Treg-based therapeutic approach.
A growing body of evidence from animal models of
transplant suggests that cell therapy with nTregs promotes
tolerance but their efﬁcacy is strictly dependent on their
Ag speciﬁcity. Importantly, to date, the ex vivo generation/
expansion of Ag-speciﬁc nTregs remains one of the major
challenges of the ﬁeld, seeking to devise a means for
inducing long-term tolerance (reviewed in 10). On the
contrary, Tr1 cells are inducible Tregs and therefore cells
of the desired Ag speciﬁcity can be easily generated. Tr1
cells can be induced in vitro and in vivo in the presence of
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tion (7) and thus can be envisaged as a therapeutic tool to
transfer immunological tolerance. That said, the efﬁcacy of
adoptive Tr1-cell therapy as well as the Ag-speciﬁcity
requirement in preclinical models of islet transplant have
thus far not been reported.
We demonstrate that Ag-speciﬁc Tr1 cells transfer stable
long-term, graft-speciﬁc, and IL-10–dependent tolerance
in a stringent model of allogeneic islet transplant, whereas,
at the same time, non–Ag-speciﬁc polyclonal Tr1 cells fail
to provide this same activity. These data set the basis for
future clinical trials with Tr1-cell therapy in type 1 diabetic
patients who underwent an islet transplant.
RESEARCH DESIGN AND METHODS
Mice and islet transplant. BALB/c, C57BL/6, and C3H female mice were
purchased from Charles River (Calco, Italy). All mice were maintained under
speciﬁc pathogen-free conditions. Diabetes was induced by intravenous
injection of 170 mg/kg streptozotocin (Sigma-Aldrich, St. Louis, MO). Glucose
level in the tail venous blood was quantiﬁed using the Glucometer Elite system
(Bayer, Wuppertal, Germany) and always measured in the morning.
Pancreatic islets were separated by density gradient centrifugation after in
situ digestion with collagenase P (Roche Applied Science, Indianapolis, IN).
After being cultured overnight at 37°C, handpicked pancreatic islets were
transplanted (300 islets/mouse) under the kidney capsule of recipient diabetic
mice, as previously described (11). A diagnosis of graft rejection was made
after two sequential glucose measurements higher than 300 mg/dl. All animal
care procedures were performed according to protocols approved by the San
Raffaele Hospital Institutional Animal Care and Use Committee (IACUC no.
350).
Two million T-cells (described below) were resuspended in 200 l PBS and
injected intravenously in diabetic recipient mice 1 day before undergoing islet
transplant.
The transplant recipient mice that did not reject the allograft 100 days after
transplant were boosted in vivo with donor-origin splenocytes. A total of 30 
10
6 splenocytes isolated from the original islet donors were injected intraperi-
toneally, and the blood glucose level was monitored daily thereafter. Long-
term tolerant C57BL/6 mice that underwent a transplant were treated with
IL-10 receptor (IL-10R) monoclonal antibody (mAb; 1B1.2 clone from
ATCC, Manassas, VA) diluted in saline solution and administered intraperito-
neally at 145, 146, and 147 days after transplant to reach a dose of 1 mg/mouse.
In vitro Tr1-cell induction. Naive splenic CD4
 T-cells were isolated from
BALB/c or C57BL/6 mice with the CD4
 T Cell Isolation Kit (Miltenyi Biotec,
Bergisch Gladbach, Germany) and the CD62L mAb-coated microbeads
(Miltenyi Biotec) following the manufacturer’s instructions. The naive T-cells
were plated at 1  10
6 cells/ml and cultured in Iscoves modiﬁed Dulbecco’s
medium (Invitrogen, Carlsbad, CA) plus 10% FBS (Logan, Basel, Switzerland).
The cells were stimulated with 10 g/ml plate-bound CD3 and 1 g/ml
soluble CD28 mAbs (BD Biosciences, San Diego, CA) for three rounds of
stimulation (for a total of 3 weeks) with or without 1,000 units/ml of human
(hu)–IL-10 (BD Pharmingen, San Diego, CA). Starting from the second round
of stimulation, 50 units/ml of IL-2 (BD Pharmingen) were added to the
cultures. All cells were cultured in humidiﬁed incubators at 37°C with 5% CO2.
In vivo Tr1-cell induction. Diabetic C57BL/6 mice received a transplant of
BALB/c islets and were treated with CD45RB mAb (MB23G2 clone from
ATCC), rapamycin (Rapamune; Wyeth Europe, Taplow, U.K.), and hu-IL-10
(BD Pharmingen). CD45RB mAb was injected intravenously at days 0, 1, and
5 after transplant at 100 g per dose. Rapamycin was diluted in water and
administered by gavage for 30 consecutive days once a day at 1 mg/kg.
hu-IL-10 (BD Pharmingen) was diluted in PBS and administered intraperito-
neally twice daily for 30 consecutive days at 0.05 g/kg. Thirty days after
transplant, the spleens were collected from mice that underwent transplant
and were manually smashed through screens. Splenic CD4
 T-cells were
magnetically puriﬁed using the CD4
 T Cell Isolation Kit (Miltenyi Biotec) to
test for the presence of Tr1 cells. Alternatively, CD4
CD25
 splenic T-cells
were puriﬁed by the CD4
 T Cell Isolation Kit and by the CD25 mAb-coated
microbeads (Miltenyi Biotec) to perform adoptive transfer experiments.
Enzyme-linked immunosorbent assay. Puriﬁed CD4
 T-cells were cultured
in 96-well plates at 0.3  10
6 cell/well in the presence of 0.5  10
6/well of
irradiated antigen-presenting cells (APCs), which consisted of spleens mag-
netically depleted of CD90
 T-cells by the use of CD90 mAb-coated mi-
crobeads (Miltenyi Biotec) from the original islet donors or a third-party
donor (i.e., C3H mice). Supernatants were collected 7 days after culture for
IL-4 and IL-10 detection. Cytokines present in the supernatants were quanti-
ﬁed by a sandwich enzyme-linked immunosorbent assay using standard
commercially available kits (Pharmingen OptEIA mouse; BD Pharmingen).
Intracellular staining. CD4
 T-cells were stimulated with 500 ng/ml 12-O-
tetradecanoylphorbol-13-acetate (TPA; Calbiochem, Merck KGaA, Darmstadt,
Germany) and 1 g/ml ionomycin (Calbiochem) for6hi nt h epresence of
Golgi Stop (BD Bioscience). Cells were then collected, washed, and stained
for 30 min at 4°C with CD4 ﬂuorescein mAb (RM4-5; BD Biosciences). The
stained cells were washed, ﬁxed, and permeabilized with saponin 20%
(Sigma-Aldrich) for 20 min at room temperature. Permeabilized cells were
stained with IL-10 phycoerythrin (JES5-16E3; eBioscience) and IL-4 APC
(11B11; BD Biosciences) mAbs. Data were acquired on FACSCanto (BD
Biosciences) and analyzed with FCS express V3 (De Novo Software, Los
Angeles, CA).
Statistics. Differences between groups were assessed using Student t test. P
values were two tailed with a conﬁdence of 95%. In all cases, two-tailed P 
0.05 was considered signiﬁcant. Islet allograft survivals were determined using
Kaplan-Meier survival curves and were compared by the log-rank test.
Analyses were performed using the Prism V4.03 software (Graph-Pad, San
Diego, CA).
RESULTS
Non–Ag-speciﬁc Tr1 cells were generated in vitro from
splenic naive CD4
CD62L
 T-cells isolated from either
BALB/c (BALB) or C57BL/6 (B6) mice. Repetitive poly-
clonal activation of naive T-cells in the presence of high
doses of IL-10 led to the generation of 20–25% of Tr1 cells
(i.e., IL-10
IL-4
), as previously demonstrated (12). The
same cells cultured in the absence of IL-10 did not
differentiate into Tr1 cells and were deﬁned as T helper 0
(Th0) cells (Fig. 1A). CD4
CD25
FoxP3
 nTregs were not
expanded in these culture conditions (data not shown).
The ability of in vitro–generated polyclonal Tr1 cells to
transfer immunological tolerance in mice undergoing allo-
geneic islet transplant was tested. A bulk population of
host-origin Tr1-enriched cells was transferred in chemi-
cally induced diabetic BALB mice the day before receiving
B6 islets. Untreated mice and mice receiving cultured Th0
cells were used as controls. Five of eight mice that
underwent a transplant receiving Tr1 cells did not reject
the graft 25 days after transplant, whereas none of the
control mice had a functional graft at the same time point
(Fig. 1B, left panel). Long-term graft survival 100 days after
transplant was observed in 50% of mice receiving Tr1 cells.
To further test the strength of Tr1-cell–mediated toler-
ance, mice that underwent transplant were rechallenged in
vivo with splenocytes isolated from the original donors
(i.e., B6 mice). Upon injection of allogeneic splenocytes,
only one of four mice rejected the graft (Fig. 1B, left
panel). Notably, long-term engrafted mice not receiving
the in vivo rechallenge with allogeneic splenocytes re-
mained normoglycemic for at least an additional 50 days
(latest time point analyzed) (data not shown). Overall, the
proportion of mice achieving long-term tolerance (i.e.,
accepting the primary graft and retaining the graft after Ag
rechallenge) upon Tr1-cell transfer in the absence of any
pharmacological treatment was 38%. On the contrary, all
untreated mice or mice receiving cultured Th0 cells re-
jected the graft by day 25 after transplant.
The stringency of an animal model of islet transplant is
inﬂuenced by the major histocompatibility complex mis-
match between donors and recipients and can be assessed
by the mean graft rejection time. The shorter the mean
rejection time of untreated mice, the higher the stringency
of the model. In our hands, untreated BALB mice that
received a transplant of B6 islets (B63BALB) have a
mean rejection time of 25  4 days. Conversely, untreated
B6 mice that receive a transplant of BALB islets
(BALB3B6) reject the graft in a mean of 15  3 days. The
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fer immunological tolerance was therefore tested also in
this latter more stringent islet transplant model. A bulk
population of host-origin Tr1-enriched cells was transferred
in chemically induced diabetic B6 mice the day before
receiving BALB islets. Untreated mice and mice receiving
cultured Th0 cells were used as controls. All mice promptly
rejected the graft irrespective of the cells transferred (Fig.
1B, right panel). In conclusion, transfer of polyclonal Tr1
cells promotes engraftment and induces long-term tolerance
after islet transplant, but its efﬁcacy is highly dependent on
the stringency of the animal model used.
We previously demonstrated that tolerance is induced in
vivo by rapamycin  IL-10 treatment via the induction of
Tr1 cells in the nonstringent model of islet transplant
(B63BALB) (11). In contrast, in the stringent islet trans-
plant model (BALB3B6), we observed that the addition of
a depleting agent (i.e., CD45RB mAb) was fundamental
for the generation of Tr1 cells in vivo (see Research Design
and Methods for treatment details) (N.G. et al., unpub-
lished observations). Accordingly, 15–20% of Tr1 cells
were found in the spleen of B6 mice that received a
transplant of BALB islets and were treated with CD45RB
mAb  rapamycin  IL-10 (Fig. 2A). We hypothesized that,
because these Tr1 cells were generated in vivo after islet
transplant, they may carry a donor Ag speciﬁcity. To test
this, splenic CD4
 T-cells isolated from treated mice that
underwent a transplant were stimulated in vitro with APCs
of the original donors (i.e., BALB mice) or third-party
donors (i.e., C3H mice). The frequency of donor-speciﬁc
Tr1 cells was signiﬁcantly higher than that of cells speciﬁc
for third-party Ag. In contrast, the frequency of splenic Tr1
cells was low in both untreated mice that underwent a
transplant and naive mice, and there was no suggestion of
any Ag speciﬁcity (Fig. 2B). The amount of IL-10 released
in culture supernatants by splenic CD4
 T-cells isolated
from treated mice that underwent a transplant upon
Ag-speciﬁc stimulation was signiﬁcantly higher in re-
sponse to the original donor Ag compared with third-party
Ag (Fig. 2C), although no differences were found in the
production of IL-4 (data not shown). These data demon-
strate the presence of Ag-speciﬁc Tr1 cells in the spleen of
B6 mice that received a transplant of BALB islets and were
treated with an IL-10–based protocol.
We tested whether, in contrast to polyclonal Tr1 cells,
the in vivo–generated Ag-speciﬁc Tr1 cells were able to
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FIG. 1. A: Naive CD4
CD62L
 T-cells isolated from the spleens of BALB (left)o rB 6( right) mice were activated with CD3 and CD28 mAbs in
the presence or absence of exogenous IL-10 for 3 weeks. The ability to produce IL-10 and IL-4 was tested by intracellular staining at the end of
the culture and upon TPA/ionomycin stimulation. The frequency of Tr1 cells (i.e., IL-10
IL-4
 cells) differentiated in the presence (IL-10) or
absence of IL-10 is reported in bold. One representative experiment of ﬁve (for BALB) and three (for B6) mice is shown. B: Chemically induced
diabetic BALB mice received a transplant of islets from B6 mice. The day before transplant, recipient mice were injected with PBS (no cells, n 
7), 2  10
6 of BALB CD4
 T-cells enriched in Tr1 cells upon culture in the presence of IL-10 (Tr1 cells, n  8), or 2  10
6 BALB CD4
 T-cells
cultured for 3 weeks in the absence of IL-10 (Th0 cells, n  4). Graft survival was monitored by glycemia levels. A graft was considered rejected
when glycemia was >300 mg/dl. At 100 days after transplant, 30  10
6 splenocytes isolated from B6 mice were injected in tolerant mice to boost their
immune system. The percentage of graft survival at various time points after transplant is shown (left). Chemically induced diabetic B6 mice received
a transplant of islets from BALB mice. The day before transplant, recipient mice were injected with PBS (no cells, n  8), 2  10
6 B6 CD4
 T-cells
enriched in Tr1 cells upon culture in the presence of IL-10 (Tr1 cells, n  6), or 2  10
6 B6 CD4
 T-cells cultured for 3 weeks in the absence of IL-10
(Th0 cells, n  2). Graft survival was monitored by glycemia levels. A graft was considered rejected when glycemia was >300 mg/dl (right).
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allogeneic islet transplant. To exclude any possible
contamination with CD4
CD25
 Tregs naturally present
in the spleen of mice that underwent a transplant,
CD4
CD25
 T-cells were puriﬁed and adoptively trans-
ferred in chemically induced diabetic B6 mice the day
before receiving BALB islets. Untreated mice and mice
receiving CD4
CD25
 T-cells isolated from the spleens of
untreated mice that underwent a transplant were used as
controls. All mice receiving T-cells enriched in donor
Ag-speciﬁc Tr1 cells had a functioning graft 25 days after
transplant, whereas none of the control mice had a func-
tional graft at the same time point. Long-term graft survival
100 days after transplant was observed in 40% of the mice
receiving Ag-speciﬁc Tr1 cells. To conﬁrm that long-term
tolerance was mediated by IL-10, IL-10R mAb was given
to long-term tolerant mice previously injected with Ag-
speciﬁc Tr1 cells. All mice promptly rejected the graft
upon IL-10R mAb treatment, strongly suggesting that
Tr1-cell therapy maintains tolerance in vivo via IL-10 (Fig.
3A). To further prove that Tr1 cells transfer tolerance in a
stringent model of islet transplant due to their Ag speci-
ﬁcity, BALB-speciﬁc CD4
CD25
 T-cells were transferred
in B6 mice receiving islets from C3H donors. Transfer of
BALB-speciﬁc Tr1 cells did not prevent rejection of C3H
islets (Fig. 3B), further proving that their functional ad-
vantage over polyclonal Tr1 cells was due to their Ag
speciﬁcity. Taken collectively, these data support the
concept that Tr1 cells, to be of a therapeutic value in the
context of islet transplant, must be donor speciﬁc.
DISCUSSION
The ﬁeld of islet transplantation would without question
beneﬁt from the introduction of new treatments that
engender stable long-term tolerance. Here we show that
cell therapy with alloAg-speciﬁc Tr1 cells promotes an
IL-10–dependent graft-speciﬁc tolerance in a stringent
A
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FIG. 2. A: Splenic CD4
 T-cells isolated from treated B6 mice that underwent a
transplant (Tx/treated, n  4), untreated B6 mice that underwent a transplant (Tx,
n  4), and naive B6 mice (naive, n  2) were cultured for 1 week in the presence
of CD3 and CD28 mAbs. The ability to produce IL-10 and IL-4 was tested by
intracellular staining at the end of the culture and upon TPA/ionomycin stimula-
tion. The frequency of Tr1 cells (i.e., IL-10
IL-4
 cells) is reported in bold. One
representative plot for each group tested is shown. B: Splenic CD4
 T-cells isolated
from treated B6 mice that underwent a transplant (Tx/treated, n  4), untreated B6
mice that underwent a transplant (Tx, n  4), and naive B6 mice (naive, n  2) were
cultured for 1 week with irradiated APCs isolated from the original donor of the
islets (BALB) (upper panels) or from unrelated third-party APCs (C3H) (lower
panels). The ability to produce IL-10 and IL-4 was tested by intracellular staining
at the end of the culture and upon TPA/ionomycin stimulation. The frequency of Tr1
cells (i.e., IL-10
IL-4
 cells) is reported in bold. One representative plot for each
group tested is shown (left). The ratio between the percentage of Tr1 cells speciﬁc
for the original donor and the percentage of Tr1 cells speciﬁc for a third-party
donor are shown (right). C: At the end of 1 week of in vitro Ag-speciﬁc stimulation,
IL-10 secretion was measured by enzyme-linked immunosorbent assay. The ratio
between IL-10 produced speciﬁcally in response to APCs from the original donor
and IL-10 produced in response to third-party APCs is shown. *P < 0.05.
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pharmacological treatment. Importantly, the efﬁcacy of
this cell therapy is strictly dependent on the Tr1-cell Ag
speciﬁcity.
Several preclinical studies have established that transfer
of Tregs restrains T-cell–mediated diseases and promotes
tolerance (4). Cotransfer of freshly isolated nTregs to-
gether with a bone marrow allograft ameliorates graft-
versus-host disease (GvHD) and facilitates engraftment in
mouse models of bone marrow transplant (BMT) (re-
viewed in 13). In these models, transfer of nTregs enriched
for alloAg speciﬁcity shows only moderately improved
efﬁcacy compared with the transfer of polyclonal nTregs
(4). In contrast, in experimental models of autoimmune
diabetes, only autoAg-speciﬁc Tregs have demonstrated
therapeutic effectiveness (4). These different results might
be ascribed to the presence of a lymphopenic environment
after BMT that supports the homeostatic expansion of
transferred Tregs and may be different in normal immuno-
competent mice. Accordingly, transfer of polyclonal
nTregs induces tolerance to skin and heart grafts only in
lymphopenic hosts reconstituted with effector T-cells
(14,15). In contrast, transfer of polyclonal nTregs in immu-
nocompetent mice that received a transplant of allogeneic
pancreatic islets (16) or skin (17) fails to block graft
rejection. To improve the efﬁcacy of cell therapy in immu-
nocompetent hosts, alloAg-speciﬁc nTregs (17,18) or high
numbers of nTregs (19) are required, although both ap-
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FIG. 3. A: Chemically induced diabetic B6 mice received a transplant of islets from BALB mice. The day before transplant, recipient mice were
injected with PBS (no cells, n  7), 2  10
6 CD4
CD25
 T-cells isolated from the spleen of B6 treated mice that underwent a transplant
(Tx/treated, n  5), or 2  10
6 CD4
CD25
 T-cells isolated from the spleen of B6 untreated mice that underwent a transplant (Tx mice, n  2).
At 150 days after transplant, tolerant mice were injected with IL-10R mAb. Graft survival was monitored by glycemia levels. A graft was
considered rejected when glycemia was >300 mg/dl. The percentage of graft survival at various time points after transplant is shown. B:
Chemically induced diabetic B6 mice received a transplant of islets from C3H mice. The day before transplant, recipient mice were injected with
PBS (no cells, n  6), or 2  10
6 CD4
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such as the administration of depleting agents, immuno-
suppression, and/or low doses of irradiation. Our data
show that the mere transfer in immunocompetent mice of
Tr1 cells promotes long-term tolerance in the absence of
any exogenous pharmacological treatment. To achieve
high efﬁcacy in a stringent islet transplant model, Tr1 cells
need to be donor speciﬁc.
We previously demonstrated, in a nonstringent mouse
model, that rapamycin  IL-10 treatment induces toler-
ance in BALB mice that received a transplant of B6 islets
(11). However, rapamycin  IL-10 treatment does not
promote tolerance in the more stringent model of B6 mice
that received a transplant of BALB islets (N.G. et al.,
unpublished observations). Interestingly, the transfer of
alloAg-speciﬁc Tr1 cells promotes long-term tolerance in
this latter stringent model, proving that cell therapy with
Tr1 cells has a therapeutic advantage over rapamycin 
IL-10 treatment. The superiority of a Tr1-cell–based ther-
apy over a pharmacological-based approach may be due to
the fact that Tr1 cells, in addition to IL-10, produce other
still unknown immunomodulatory factors that can power-
fully control undesired immune responses. Alternatively,
the IL-10 physiologically produced upon Ag-speciﬁc Tr1-
cell activation may exclusively exert an immunomodula-
tory activity, whereas the exogenous administration of a
ﬁxed dose of recombinant IL-10 exerts an additional
immunostimulatory action, as previously demonstrated
(20).
IL-10 is a soluble factor that plays a central role in
controlling inﬂammatory processes, suppressing T-cell re-
sponses, and maintaining immunological tolerance after
transplant (20). Bacchetta et al. showed that severe com-
bined immunodeﬁcient patients who successfully received
a transplant of HLA-mismatched hematopoietic stem cells
have circulating host-reactive T-cell clones producing high
levels of IL-10 in the absence of IL-4. The presence of these
cells correlates with the absence of GvHD as well as
long-term graft tolerance without the need of immunosup-
pression (21). Similarly, increased frequencies of IL-10–
producing Tr1 cells in thalassemic patients with a
persistent state of mixed chimerism after a successful
BMT have recently been noted (22). Other groups have
reported that high spontaneous IL-10 production by pe-
ripheral blood before BMT is associated with a low
incidence of GvHD and transplant-related mortality
(23,24). Patients who spontaneously develop tolerance to
kidney or liver allografts have circulating Tr1 cells, which
suppress naive T-cell responses via production of IL-10
and transforming growth factor- (25). A new consensus
on the immunomodulatory role of IL-10 also in patients
who underwent islet transplant has begun to emerge (9)
and our preclinical data corroborate this new notion.
Stable long-term tolerance to allogeneic transplanted islets
is indeed strictly IL-10 dependent, regardless of the ap-
proach used, either pharmacologically or cellularly based.
Long-term tolerance mediated by the administration of
rapamycin  IL-10 (11), or by the transfer of alloAg-
speciﬁc Tr1 cells, is indeed rapidly broken upon IL-10R
mAb administration.
Taken together, our results set the basis for the inves-
tigation of a Tr1-cell therapy in patients undergoing islet
transplant. Importantly, type 1 diabetic subjects who re-
ceive a transplant of allogeneic islets not only develop new
alloreactive immune responses but also have preexisting
autoreactive immunity. We previously demonstrated that
Tr1 cells generated in vivo in NOD mice control diabetes
development by blocking the migration of diabetogenic
T-cells in the pancreas (26), thus supporting the Tr1 cell’s
ability to restrain autoimmune reactions. However, it
remains to be determined whether alloreactive speciﬁc
Tr1 cells can contain also autoimmune responses by
bystander suppression, as demonstrated in other settings
(27).
A clinical trial of adoptive therapy with ex vivo–gener-
ated host-speciﬁc Tr1 cells to prevent the occurrence of
GvHD in leukemia patients who received a transplant of
haploidentical hematopoietic stem cells is already ongoing
in our institute. Data from this effort, to date, demonstrate
the feasibility and safety of this approach (7) providing
strong rationale for its consideration as an application to
islet transplant for patients with type 1 diabetes (3). We
recently identiﬁed a population of tolerogenic dendritic
cells (DCs), termed DC-10, that is present in the peripheral
blood and secondary lymphoid organs of humans and can
be differentiated in vitro from peripheral blood monocytes
in the presence of exogenous IL-10. DC-10 cells are potent
inducers of alloAg-speciﬁc Tr1 cells (S. Gregori et al.,
unpublished data). We are currently developing this pro-
tocol to evaluate whether DC-10 isolated from the spleen
of pancreas donors can induce donor-speciﬁc Tr1 cells.
One should not forget that a Tr1-cell–based therapy may
not by itself account for islet engraftment, long-term
function, and immunological tolerance, in contrast to what
we observed in preclinical animal models. Cell therapy
with Tregs in type 1 diabetic patients might therefore need
to be associated, albeit temporarily, with a ﬁnely tuned
immunosuppressive treatment. Importantly, the inﬂuence
of the commonly used immunosuppressive drugs on Tr1-
cell induction, function, and survival is largely unknown.
Much effort has been recently devoted to the deﬁnition of
a Treg-permissive immunosuppressive therapy to be ad-
ministered with Ag-speciﬁc Tr1 cells and then slowly
tapered down to achieve drug-free long-term graft toler-
ance (3).
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